Progression of Cerebral Atrophy and White Matter Hyperintensities in Patients With Type 2 Diabetes

Jeroen de Bresser, MD1,2
Audrey M. Tieleman, MD, PhD3
Esther van den Berg, PhD1
Yael D. Reijmer, MSc1
Cynthia Jongen, PhD1,2
L. Jaap Kappelle, MD, PhD1
Willem P. Mali, MD, PhD3
Max A. Viergever, PhD2
Geert Jan Bissel, MD, PhD1
on behalf of the Utrecht Diabetic Encephalopathy Study Group*

OBJECTIVE — Type 2 diabetes is associated with a moderate degree of cerebral atrophy and a higher white matter hyperintensity (WMH) volume. How these brain-imaging abnormalities evolve over time is unknown. The present study aims to quantify cerebral atrophy and WMH progression over 4 years in type 2 diabetes.

RESEARCH DESIGN AND METHODS — A total of 55 patients with type 2 diabetes and 28 age-, sex-, and IQ-matched control participants had two 1.5T magnetic resonance imaging scans with a 4-year interval. Volumetric measurements of total brain, peripheral cerebrospinal fluid (CSF), lateral ventricles, and WMH were performed with k-nearest neighbor–based probabilistic segmentation. All volumes were expressed as percentage of intracranial volume. Linear regression analyses, adjusted for age and sex, were performed to compare brain volumes between the groups and to identify determinants of volumetric change within the type 2 diabetic group.

RESULTS — At baseline, patients with type 2 diabetes had a significantly smaller total brain volume and larger peripheral CSF volume than control participants. In both groups, all volumes showed a significant change over time. Patients with type 2 diabetes had a greater increase in lateral ventricular volume than control participants (mean adjusted between-group difference in change over time [95% CI]: 0.11% in 4 years [0.00 to 0.22], P = 0.047).

CONCLUSIONS — The greater increase in lateral ventricular volume over time in patients with type 2 diabetes compared with control participants shows that type 2 diabetes is associated with a slow increase of cerebral atrophy over the course of years.

From the 1Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands; the 2Image Sciences Institute, University Medical Center Utrecht, Utrecht, the Netherlands; and the 3Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands.

Corresponding author: Jeroen de Bresser, j.debresser@umcutrecht.nl.

Received 15 October 2009 and accepted 7 March 2010. Published ahead of print at http://care.diabetesjournals.org on 18 March 2010. DOI: 10.2337/dc09-1923.

*Members of the Utrecht Diabetic Encephalopathy Study Group can be found in the Appendix.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
volumetric measurements impossible. This left a total of 83 participants (55 patients and 28 control participants; mean follow-up time: 4.1 ± 0.4 years) for inclusion in the present study.

Age and sex distribution and estimated IQ at baseline were not significantly different between participants included (n = 83) and not included (n = 77) in this follow-up MRI study. Importantly, baseline brain volumes (7) were also not significantly different between participants and nonparticipants. The study was approved by the medical ethics committee of the University Medical Center Utrecht, and all participants signed an informed consent form.

Medical history and physical examination
At baseline and follow-up, the same standardized interview was used to question participants about level of education (seven categories), medication use, hypercholesterolemia, smoking, history of a macrovascular event (myocardial infarction or stroke requiring hospitalization or surgical or endovascular treatment of atherosclerotic arterial disease), and diabetes duration. At baseline and follow-up, weight and height were measured and blood samples were taken to determine A1C, fasting glucose, and cholesterol levels. At baseline, blood pressure was measured automatically at home on 10 different time points during the day. At follow-up, blood pressure was measured in a seated position at three time points during the half-day visit. Mean arterial pressures were calculated from these measurements. Hypertension was defined as a systolic blood pressure >160 mmHg or diastolic blood pressure >95 mmHg or self-reported use of blood pressure–lowering drugs prescribed primarily for hypertension. Hypercholesterolemia was defined as a fasting cholesterol >6.2 mmol/l or self-reported use of lipid-lowering drugs. BMI was calculated as weight (in kilograms) divided by the square of height (in meters). All participants had a neurological examination at baseline and follow-up; none of the participants had focal abnormalities suggestive of central lesions, such as infarcts.

IQ was estimated with the Dutch version of the National Adult Reading Test, which is generally accepted to reflect the premorbid level of intellectual functioning (8,9). To control for selective loss to follow-up, the cognitive status of participants (a week after participation in the follow-up examination) and nonparticipants was assessed with the modified Dutch version of the Telephone Interview for Cognitive Status (TICS-m), a screening instrument designed to identify people with dementia (10,11). A cutoff score of 28 is indicative of cognitive impairment (12).

MRI scanning protocol
MRI scans were acquired at baseline and follow-up on a 1.5T Philips magnetic resonance system using a standardized protocol (38 contiguous slices, voxelsize: 0.9 × 0.9 × 4.0 mm) and consisted of an axial T1 (repetition time in ms [TR]: 234, echo time in ms [TE]: 2), T2 (TR: 2,200, TE: 100), proton density (PD) (TR: 2,200, TE: 11), inversion recovery (IR) (TR: 2,919, TE: 22, inversion time in ms [TI]: 410), and fluid-attenuated inversion recovery (FLAIR) (TR: 6,000, TE: 100, TI: 2,000).

Image processing
On both time points, all images (T1, T2, PD, and IR) of each participant were rigidly registered to the FLAIR image by using Elastix (13). Scan inhomogeneities were corrected by a shading correction algorithm (14).

To exclude all nonbrain and non-cerebrospinal fluid (CSF) tissue, a brain mask was created for every participant using all baseline images in a k-means–clustering algorithm with eight clusters (7). The clusters that contained brain and CSF were combined, and additional nonbrain and non-CSF structures in the formed mask were automatically excluded and holes were filled by using a standardized protocol of morphological operators. A 3-voxel dilation of the mask was performed to include all CSF, and the result was manually adjusted to only contain tissue above the foramen magnum.

To construct a follow-up mask with the same brain coverage, the baseline FLAIR was rigidly registered to the follow-up FLAIR of the same participant, and the resulting transform parameters were used to transform the baseline brain mask (13). A standardized combination of morphological operators was applied to fill holes and smooth the follow-up mask. The uncorrected FLAIR images were multiplied voxelwise by the binary brain mask, followed by a shading correction to provide better correction (14).

For the volume measurements on one time point, the brain mask, FLAIR, and IR were used. Volumes were measured by k-nearest neighbor–based probabilistic segmentation, an automatic and validated approach to brain segmentation (15). This method is based on manually classified training data, which consists of FLAIR and IR images of 10 matched subjects with a different extent of cerebral atrophy and WMH made by an identical scanning protocol to the images in this study. Gray and white matter, peripheral CSF (CSF without lateral ventricles), lateral ventricular, and WMH volume were automatically classified.

The results of the probabilistic classification of all tissues were visually checked for all participants, and incorrectly classified images were excluded. In two participants, a small meningioma was found, which was manually excluded. To reduce the effects of noise, the WMH classification was thresholded on a 0.5 probability, after which isolated classified voxels were automatically excluded. The automated segmentation tends to classify the gliotic core around infarcts as WMH. Because this confounds the measurement of WMH volume, infarcts were manually segmented from the WMH volume and added to the total brain volume. The total volume of the individual tissues was calculated by multiplying the probabilities by the voxel volume. To correct for between-subject differences in intracranial volume (volume of all classified tissues combined), all baseline and follow-up volumes were expressed as a percentage of intracranial volume. Total brain volume (gray and white matter + WMH + infarcts) was calculated on both time points. The total brain, peripheral CSF, lateral ventricular, and WMH volume were analyzed.

Statistical analysis
Participant characteristics were compared between the type 2 diabetic group and the control group using independent-samples t tests. TICS-m scores were compared between participants and nonparticipants at the follow-up examination by an independent-samples t test and differences in loss to follow-up between groups were assessed by Pearson χ² tests. Within-group changes in brain volumes over time were assessed by using paired t tests. Because of nonnormal distribution (Kolmogorov-Smirnov, P < 0.05), progression of WMH volume was analyzed by a Wilcoxon signed-rank test. Linear regression analyses adjusted for age and sex were performed to assess the relationship between baseline brain volumes and...
(group and the relationship between volume change over time and group. Baseline WMH volume was multiplied by 100 and naturally log transformed because of non-normal distribution. Additionally, separate analyses were done for men and women, because differences in cerebral tissue volumes were found at the baseline examination (7).

To identify possible determinants of baseline brain volume and volume change over time, linear regression analyses adjusted for age and sex were performed within the type 2 diabetic group. Determinants that were considered included diabetes duration, A1C levels, mean arterial pressure, hypertension, total cholesterol levels, hypercholesterolemia, BMI, and history of a macrovascular event.

RESULTS — Table 1 shows the baseline characteristics of the patients with type 2 diabetes and the control participants. The groups are similar with regard to age, sex distribution, and estimated IQ ($P > 0.05$). As expected, the groups differed on vascular risk factors and glycemic control. At follow-up, nine patients and three control participants had new brain infarcts. Levels of risk factors remained unchanged over time.

A TICS-m was obtained from 51 (76% with diabetes) of 67 nonparticipants at follow-up who were still alive and could be contacted and from 79 (66% with diabetes) of 83 participants. The TICS-m score was similar and normally distributed for participants and nonparticipants (participants mean 36.9 ± 4.4, nonparticipants 35.1 ± 6.0, $P > 0.05$). Among all nonparticipants, three patients with type 2 diabetes (3% of baseline sample) and two control participants (4% of baseline) had marked cognitive impairment based on caregiver-reported dementia or a TICS-m score $< 28$ ($X^2 \left(1 \right) = 0.34, P = 0.56$) (10). Table 2 shows baseline volumes and differences between baseline and follow-up volumes. In both groups, total brain volume decreased over time and peripheral CSF, lateral ventricular, and WMH volume increased over time (all $P \leq 0.001$ in both groups).

At baseline, patients with type 2 diabetes had a significantly smaller total brain volume (adjusted difference between type 2 diabetes and control group [95% CI] $-1.36\% \left[-2.31 \text{ to } -0.40\right], P = 0.006$) and larger peripheral CSF volume (0.98% [0.07 to 1.90], $P = 0.036$). The lateral ventricular volume showed a greater increase over time in patients with type 2 diabetes than in control participants (adjusted difference in change over time between type 2 diabetes and control group [95% CI] 0.11% in 4 years [0.00 to 0.22], $P = 0.047$). Relative to the baseline ventricular volume, this reflects a 3.6% larger increase in the diabetic than in the nonparticipating control group.
Cerebral atrophy and WMH in type 2 diabetes

Table 3—Relationship between baseline determinants and baseline volumes and volume change over time in patients with type 2 diabetes

| Baseline | Total brain | Peripheral CSF | Lateral ventricles | WMH* |
|----------|-------------|----------------|--------------------|------|
| Age (per 5 years) | −1.00 (−1.59 to −0.41)† | 0.93 (0.38 to 1.48)† | 0.07 (−0.20 to 0.35) | 0.17 (−0.08 to 0.43) |
| Male sex | −1.16 (−2.43 to 0.10) | 1.01 (−0.17 to 2.19) | 0.16 (−0.42 to 0.74) | −0.23 (−0.77 to 0.32) |
| Diabetes duration (per 5 years) | 0.03 (−0.49 to 0.59) | 0.03 (−0.46 to 0.52) | −0.06 (−0.30 to 0.18) | −0.16 (−0.37 to 0.06) |
| A1C level (%) | 0.00 (−0.58 to 0.57) | −0.05 (−0.58 to 0.49) | 0.05 (−0.22 to 0.31) | −0.02 (−0.26 to 0.23) |
| Mean arterial pressure (per 10 mmHg) | 0.02 (−0.45 to 0.48) | −0.01 (−0.45 to 0.42) | −0.01 (−0.22 to 0.21) | 0.11 (−0.09 to 0.31) |
| Hypertension† | −0.49 (−1.89 to 0.92) | 0.28 (−1.04 to 1.60) | 0.20 (−0.45 to 0.85) | −0.22 (−0.82 to 0.39) |
| Total cholesterol (mmol/l) | −0.28 (−1.00 to 0.44) | 0.06 (−0.62 to 0.73) | 0.23 (−0.10 to 0.55) | 0.00 (−0.31 to 0.31) |
| Hypercholesterolemia§ | 0.22 (−1.20 to 1.64) | 0.08 (−1.25 to 1.42) | −0.31 (−0.96 to 0.34) | −0.04 (−0.65 to 0.57) |
| BMI (kg/m²) | −0.05 (−0.21 to 0.12) | 0.10 (−0.05 to 0.25) | −0.05 (−0.13 to 0.02) | −0.03 (−0.10 to 0.04) |
| Macrovascular event¶ | −1.11 (−2.49 to 0.26) | 0.86 (−0.44 to 2.16) | 0.24 (−0.41 to 0.88) | −0.15 (−0.75 to 0.46) |

Longitudinal change over 4 years

| Age (per 5 years) | −0.25 (−0.42 to −0.08)† | 0.21 (0.05 to 0.36)† | 0.04 (−0.02 to 0.10) | 0.01 (−0.03 to 0.06) |
| Male sex | −0.06 (−0.42 to 0.31) | 0.12 (−0.21 to 0.45) | −0.06 (−0.20 to 0.07) | −0.06 (−0.16 to 0.04) |
| Diabetes duration (per 5 years) | 0.07 (−0.08 to 0.22) | −0.05 (−0.19 to 0.08) | −0.01 (−0.07 to 0.04) | −0.01 (−0.05 to 0.03) |
| A1C level (%) | 0.02 (−0.15 to 0.18) | −0.05 (−0.20 to 0.10) | 0.03 (−0.03 to 0.10) | 0.03 (−0.01 to 0.08) |
| Mean arterial pressure (per 10 mmHg) | −0.08 (−0.21 to 0.06) | 0.06 (−0.06 to 0.18) | 0.02 (−0.04 to 0.07) | −0.01 (−0.04 to 0.03) |
| Hypertension† | −0.43 (−0.81 to −0.04)† | 0.49 (0.15 to 0.83)† | −0.06 (−0.22 to 0.09) | −0.06 (−0.17 to 0.05) |
| Total cholesterol (mmol/l) | −0.04 (−0.25 to 0.16) | −0.01 (−0.20 to 0.18) | 0.05 (−0.03 to 0.13) | 0.00 (−0.06 to 0.06) |
| Hypercholesterolemia§ | 0.01 (−0.40 to 0.42) | 0.03 (−0.35 to 0.40) | −0.03 (−0.19 to 0.12) | −0.02 (−0.13 to 0.09) |
| BMI (kg/m²) | −0.01 (−0.06 to 0.04) | 0.02 (−0.02 to 0.06) | −0.01 (−0.03 to 0.01) | 0.00 (−0.02 to 0.01) |
| Macrovascular event¶ | −0.12 (−0.52 to 0.29) | 0.12 (−0.25 to 0.49) | 0.00 (−0.15 to 0.15) | 0.04 (−0.07 to 0.15) |

Data are regression B coefficients (95% CI) for each determinant, adjusted for age and sex. Baseline volumes and changes in volumes over time are described separately. Relative total brain volume decreases and relative peripheral CSF, lateral ventricular, and WMH volume increases over time. Therefore, negative B values in change over time reflect a greater decrease in relative total brain volume, whereas in the other volumes positive B values reflect a greater increase of these volumes. *Relative baseline WMH volumes were multiplied by 100 and naturally log transformed. †P < 0.01. ‡Defined as a systolic blood pressure >160 mmHg or diastolic blood pressure >95 mmHg or self-reported use of blood pressure-lowering drugs prescribed primarily for hypertension. §Defined as a fasting cholesterol >6.2 mmol/l or self-reported use of lipid-lowering drugs. ¶Defined as a myocardial infarction or stroke requiring hospitalization or surgical or endovascular treatment of atherosclerotic arterial disease. ½P < 0.05.

control group (relative increase in ventricular volume: patients: 15.2 ± 12.9%, control participants: 11.6 ± 7.8%). Total brain, peripheral CSF, and WMH volume showed no significant between-group differences in change over time (P > 0.05). At follow-up, 14 control participants had impaired fasting glucose levels (5.6–6.9 mmol/l). Brain volumes at baseline and changes in volume over time in this group were similar to the other control participants. Moreover, if these 14 individuals were removed from the comparison between the diabetic and control group, the results remained essentially the same.

In separate analyses for individuals below and above the age of 65 years, the differences between the diabetic and control group remained largely identical (data not shown). In separate analyses for men and women, female patients with type 2 diabetes compared with female control participants had a smaller baseline total brain volume (−2.07% [−3.36 to −0.78], P = 0.002), a larger baseline peripheral CSF (1.28% [0.09 to 2.47], P = 0.036) and lateral ventricular (0.78% [0.25 to 1.32], P = 0.005) volume, and a greater increase in lateral ventricular volume over time (0.21% in 4 years [0.04 to 0.37], P = 0.016). Although the direction of these effects were similar in male participants, no significant baseline or longitudinal between-group differences were found for male participants (P > 0.05).

In Table 3, the secondary analyses on metabolic and vascular risk factors within the type 2 diabetic group are shown adjusted for age and sex. Increasing age was associated with a smaller total brain volume (volume difference per 5-year increase of age [95% CI] −1.00% [−1.59 to −0.41], P = 0.001) and a larger peripheral CSF volume (0.93% [0.38 to 1.48], P = 0.001). Increasing age was also associated with a greater decrease in total brain volume over time (difference in change over time per 5-year increase of age −0.06% per year [−0.10 to −0.02], P = 0.003) and a greater increase in peripheral CSF volume (0.05% per year [0.01 to 0.09], P = 0.010). The presence of hypertension at baseline was not associated with baseline brain volumes, but hypertension was associated with a greater decrease in total brain volume over time (difference in change over time between patients with hypertension versus no hypertension −0.10% per year [−0.20 to −0.01], P = 0.033) and a greater increase in peripheral CSF volume (0.12% per year [0.04 to 0.20], P = 0.006). No significant associations between baseline brain volumes or brain volume change and sex, diabetes duration, A1C level, mean arterial pressure, total cholesterol levels, hypercholesterolemia, BMI, and history of a macrovascular event were found (P > 0.05).

**CONCLUSIONS** — At baseline patients with type 2 diabetes had more cerebral atrophy than control participants. Both the control and the type 2 diabetic group showed a significant progression of cerebral atrophy and WMH volume over 4 years. Patients with type 2 diabetes had
a greater increase in lateral ventricular volume than control participants. In explorative analyses on risk factors within the type 2 diabetic group, increasing age was associated with more cerebral atrophy and increasing age and the presence of hypertension at baseline were associated with greater progression of cerebral atrophy.

The baseline findings of our study are in line with previous cross-sectional studies, which consistently report an association between type 2 diabetes and modest cerebral atrophy (rev. in 3). To the best of our knowledge, no longitudinal studies that specifically addressed progression of cerebral atrophy over time in type 2 diabetes have been published. However, in a longitudinal study on cardiovascular risk factors and dementia in the elderly, diabetes was found to be associated with a greater increase in lateral ventricular volume (16). Moreover, some cross-sectional studies observed an association between diabetes duration and severity of cerebral atrophy (6,17) but not invariably (7). In combination with the results of these previous studies, our results suggest that cerebral atrophy in patients with type 2 diabetes progresses only slowly relative to control participants over the course of years. Hence, the average rate of decline in patients with type 2 diabetes stayed within the range of normal ageing and does not approach the accelerated loss that is observed in disease states such as Alzheimer’s disease (18). It is important to note that in our study population, cognitive decline was also not accelerated in the type 2 diabetic group relative to control participants (10).

Cross-sectional studies on the association between type 2 diabetes and WMH, as assessed with visual rating scales, showed inconsistent results (rev. in 4). However, when detailed rating scales were used, a modest association with deep WMH was observed (5,8). Recent longitudinal studies (19,20) on the association between WMH progression and vascular risk factors in the elderly reported an association between diabetes and an increased WMH progression rate. We found no significant association between type 2 diabetes and WMH volume for cross-sectional as well as longitudinal measurements in the present study, whereas we did observe an association in our baseline cohort (7). This discrepancy can be explained by the relatively large interindividual variability in WMH volume, the small difference in WMH volume between groups combined with the relatively limited sample size of the present study. Volumetric methods that can also make a distinction in periventricular and deep WMH and a larger sample size are needed to look at this association in more detail.

The sex-related differences in baseline brain volumes between groups observed in our study were comparable to the differences found in our baseline study in which between-group brain volume differences were also only significant for female participants (7). Previous studies on cognitive functioning or dementia in patients with diabetes did not observe sex-specific increases in the rate of cognitive decrements (2). However, it must be noted that the effect of sex on brain volume change and cognition in diabetes has not yet been analyzed systematically, and this is a topic that will need to be addressed in further studies.

Relatively few studies have specifically examined metabolic and vascular determinants of brain-imaging abnormalities in patients with type 2 diabetes. Cross-sectional studies (7,17,21,22) report hypertension, diabetes duration, and history of macrovascular events as determinants of cerebral atrophy and diabetes duration as a determinant of WMH volume. In the present study, hypertension was a determinant of cerebral atrophy progression. Cross-sectional studies in community-dwelling elderly subjects showed A1C level as a determinant of WMH volume and A1C and BMI as determinants of cerebral atrophy (23,24). Furthermore, in longitudinal population-based studies, not specifically in individuals with diabetes, a history of stroke was found as a determinant of WMH progression, and A1C levels, and BMI and severe WMH were found as determinants of cerebral atrophy progression (19,24). Studies on cognitive dysfunction in type 2 diabetes have identified both vascular factors and elevated A1C as possible determinants (8,25), but results are not always consistent across studies. Importantly, no causality can be inferred from such associations. Although experimental studies identify several possible mechanisms that may contribute to cerebral damage in type 2 diabetes, including glucose toxicity, vascular disturbances, and abnormal insulin signaling in the brain, it is yet unclear which of these factors are the main causal factors of cerebral damage in humans (2).

The strength of the present study is the prospective design in combination with precise automatic brain volume measurements and detailed assessment of metabolic and vascular determinants in patients and control participants. The observed changes in brain volumes over time are well outside the error of measurement of our method. Limitations include the loss to follow-up, which can lead to possible selection bias. Nevertheless, compared with the participants at follow-up, nonparticipants were similar in age, sex distribution, estimated IQ, and baseline brain volumes. The results of the TICS-m also show no selection bias due to drop out of participants with severely impaired cognitive functioning. However, the relatively healthy patient population and the risk factor profile of the control participants could have underestimated the effects of type 2 diabetes. Finally, the analyses of the determinants were affected by the modest sample size and difficulties inherent to the assessment of these determinants. Diabetes duration, for example, cannot be firmly established because diabetes develops insidiously and tends to be undiagnosed during the first years after onset. In addition, the actual levels of risk factors such as A1C and blood pressure, change over time and under the influence of treatment.

In conclusion, the greater increase in lateral ventricular volume over time in patients with type 2 diabetes as compared with control participants shows that type 2 diabetes is associated with a slow increase of cerebral atrophy over the course of years.

**Acknowledgments** — This study was financially supported by grant 2003.01.004 of the Dutch Diabetes Research Foundation and by a high potential grant from Utrecht University. The authors thank P. Anbeek, S. Klein, M. Staring, and J. Pluim for supplying software.

No potential conflicts of interest relevant to this article were reported.

**APPENDIX** — The Utrecht Diabetic Encephalopathy Study Group consists of (in alphabetical order): A. Algra, E.v.d.B., G.J.B., A.M.A. Brands, M.A. Breedijk, J.d.B., J. van Gijn, W.H. Gispen, J. van der Grond, E.H.F. de Haan, A.C. van Huffelen, C.J., L.J.K., R.P.C. Kessels, W.P.M., S.M. Manschot, J.P.W. Pluim, Y.D.R., G.E.H.M. Rutten, A.M.T., H.W. de Valk, M.A.V.
Cerebral atrophy and WMH in type 2 diabetes

References
1. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004;490:169–175
2. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5:64–74
3. Jongen C, Biessels GJ. Structural brain imaging in diabetes: a methodological perspective. Eur J Pharmacol 2008;585:208–218
4. van Harten B, Oosterman JM, Potter van Loon BJ, Scheltens P, Weinstein HC, van der Grond J. Brain lesions on MRI in elderly patients with type 2 diabetes mellitus. Eur Neurol 2007;57:70–74
5. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004;490:169–175
6. van den Berg E, Reijmer YD, de Bresser J, Biessels GJ, Viergever MA, Plum JF. Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia 2010;53:58–65
7. Welsh KA, Breitner JCS, Magruder-Habib KM. Detection of dementia in the elderly using telephone screening of cognitive status. NBN 1993;6:103–110
8. Krooks VC, Clark L, Petitti DB, Chiu H, Chiu V. Validation of multi-stage telephone-based identification of cognitive impairment and dementia. BMC Neurol 2005;5:8
9. Klein S, Staring M, Murphy K, Viergever MA, Pluim JPW. Elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med Imaging. 2010;29:196–205
10. Likar B, Viergever MA, Pernus F. Retrospective correction of MR intensity homogeneity by information minimization. IEEE Trans Med Imaging 2001;20:1398–1410
11. Anbeek P, Vincken KL, van Bochove GS, van Osch MJ, van der Grond J. Probabilistic segmentation of brain tissue in MR imaging. NeuroImage 2005;27:795–804
12. Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, Lee SE, Lee JY, Aizenstein HJ, Meltzer CC, Liu Y, Toga AW, Becker JT. Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia. Alzheimer Dis Assoc Disord 2007;21:14–24
13. Sacczynski JS, Siggurdsson S, Jonsson PV, Einiksdottir G, Olafsdottir E, Kjartansson O, Harris TB, van Buchem MA, Gudnason V, Launer LJ. Glycemic status and brain injury in older persons: the age gene/environment susceptibility: Reykjavik Study. Diabetes Care 2009;32:1608–1613
14. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 2005;65:119–124
15. Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L, Poggesi A, Inzitari D, Erkinjuntti T, Wahlund LO, Waldemar G, Schmidt R, Scheltens P, Barkhof F. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability Study. Stroke 2008;39:1414–1420
16. Enzinger C, Fazekas F, Matthews PM, Ropele S, Schmidt H, Smith S, Schmidt R. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 2005;64:1704–1711
17. Cukierman-Yaffe T, Gerstein HC, Williams JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the Action to Control Cardiovascular Risk in Diabetes (ACCORD-MIND) Trial. Diabetes Care 2009;32:221–226